DR. SEBASTIAN HEERSINK TO PERFORM 1ST iDOSE TR IN THE STATE OF ALABAMA

Eye Center South in Dothan is proud to announce the availability of iDose® TR (travoprost intraocular implant) 75 mcg. iDose TR is a new, FDA approved treatment that is designed to provide long duration, continuous drug therapy directly inside the eye, helping patients take better control over the elevated eye pressure associated with open-angle glaucoma or ocular hypertension.

Developed by Glaukos, iDose TR reduces high or elevated pressure within the eye by automatically releasing the same type of medication used for decades in the most commonly prescribed eye drops. During a clinical study, 8 out of 10 patients did not need prescription eye drops 12 months after administration of iDose TR. iDose TR may be particularly beneficial for patients who have difficulty adhering to a daily medication regimen or whose condition is uncontrolled on topical glaucoma medications.

“Eye Center South is dedicated to providing our patients with the most advanced treatment options available,” said Dr. Sebastian Heersink for Eye Center South. “iDose TR represents a significant development in how we can proactively address glaucoma care, and we are proud to be among the first practices in the State of Alabama to make this therapy available.” If you have patients who would benefit from this new treatment, please contact us for an appointment at our Dothan clinic.

For more information about iDose TR, click the website link
https://www.idosetrhcp.com/about-idose/